APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pancreatic Endocrine Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pancreatic Endocrine Tumor Drug Industry Growth and Trends Forecast to 2032

Report ID 174022030126 December 202591 pages

Choose your research edition.

Industry ResearchPancreatic Endocrine Tumor Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Pancreatic Endocrine Tumor Drug Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Pancreatic Endocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pancreatic Endocrine Tumor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Pancreatic Endocrine Tumor Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pancreatic Endocrine Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pancreatic Endocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pancreatic Endocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pancreatic Endocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pancreatic Endocrine Tumor Drug include Ipsen S.A., MediaPharma s.r.l., OXiGENE, Inc., Jiangsu Hengrui Medicine Co., Ltd. and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pancreatic Endocrine Tumor Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pancreatic Endocrine Tumor Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pancreatic Endocrine Tumor Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pancreatic Endocrine Tumor Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pancreatic Endocrine Tumor Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pancreatic Endocrine Tumor Drug Market by Company

Ipsen S.A.

MediaPharma s.r.l.

OXiGENE, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Pancreatic Endocrine Tumor Drug Segment by Type

Buparlisib Hydrochloride

Dovitinib Lactate

Fosbretabulin Tromethamine

Lanreotide Acetate

MPHE-001B

Others

Pancreatic Endocrine Tumor Drug Segment by Application

Clinic

Research Center

Hospital

Pancreatic Endocrine Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pancreatic Endocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pancreatic Endocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pancreatic Endocrine Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pancreatic Endocrine Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pancreatic Endocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Buparlisib Hydrochloride Table 2. Major Company of Dovitinib Lactate Table 3. Major Company of Fosbretabulin Tromethamine Table 4. Major Company of Lanreotide Acetate Table 5. Major Company of MPHE-001B Table 6. Major Company of Others Table 7. Global Pancreatic Endocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 9. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Pancreatic Endocrine Tumor Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 14. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Pancreatic Endocrine Tumor Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Pancreatic Endocrine Tumor Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 19. North America Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 21. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 23. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 25. Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 27. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Pancreatic Endocrine Tumor Drug Industry Trends Table 29. Pancreatic Endocrine Tumor Drug Industry Drivers Table 30. Pancreatic Endocrine Tumor Drug Industry Opportunities and Challenges Table 31. Pancreatic Endocrine Tumor Drug Industry Restraints Table 32. Global Pancreatic Endocrine Tumor Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Company (2021-2026) Table 34. Global Pancreatic Endocrine Tumor Drug Sales by Company (2021-2026) & (W Units) Table 35. Global Pancreatic Endocrine Tumor Drug Sales Share by Company (2021-2026) Table 36. Global Pancreatic Endocrine Tumor Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Pancreatic Endocrine Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Pancreatic Endocrine Tumor Drug Major Company Production Sites and Headquarters Table 39. Global Pancreatic Endocrine Tumor Drug Company, Product Type & Application Table 40. Global Pancreatic Endocrine Tumor Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Pancreatic Endocrine Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Pancreatic Endocrine Tumor Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Pancreatic Endocrine Tumor Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Pancreatic Endocrine Tumor Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Pancreatic Endocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Pancreatic Endocrine Tumor Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Pancreatic Endocrine Tumor Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Pancreatic Endocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Pancreatic Endocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Pancreatic Endocrine Tumor Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 61. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Pancreatic Endocrine Tumor Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Pancreatic Endocrine Tumor Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 66. North America Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 68. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 70. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 72. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 74. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Ipsen S.A. Company Information Table 76. Ipsen S.A. Business Overview Table 77. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio Table 79. Ipsen S.A. Recent Development Table 80. MediaPharma s.r.l. Company Information Table 81. MediaPharma s.r.l. Business Overview Table 82. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio Table 84. MediaPharma s.r.l. Recent Development Table 85. OXiGENE, Inc. Company Information Table 86. OXiGENE, Inc. Business Overview Table 87. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio Table 89. OXiGENE, Inc. Recent Development Table 90. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 91. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 92. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio Table 94. Jiangsu Hengrui Medicine Co., Ltd. Recent Development Table 95. Novartis AG Company Information Table 96. Novartis AG Business Overview Table 97. Novartis AG Pancreatic Endocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio Table 99. Novartis AG Recent Development Table 100. North America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 101. North America Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 102. North America Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 103. North America Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 104. North America Pancreatic Endocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 105. North America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 106. North America Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 107. North America Pancreatic Endocrine Tumor Drug Market Share by Country (2021-2026) Table 108. North America Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 109. North America Pancreatic Endocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 110. Europe Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 111. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 112. Europe Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 113. Europe Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 114. Europe Pancreatic Endocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 115. Europe Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 116. Europe Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 117. Europe Pancreatic Endocrine Tumor Drug Market Share by Country (2021-2026) Table 118. Europe Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 119. Europe Pancreatic Endocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 120. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 121. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 122. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 123. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 124. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 125. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 126. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 127. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Share by Country (2021-2026) Table 128. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 129. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 130. Latin America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 131. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 132. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 133. Latin America Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 134. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 135. Latin America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 136. Latin America Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 137. Latin America Pancreatic Endocrine Tumor Drug Market Share by Country (2021-2026) Table 138. Latin America Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 139. Latin America Pancreatic Endocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 140. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 141. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 142. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 143. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 144. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 145. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 146. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 147. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Share by Country (2021-2026) Table 148. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 149. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Pancreatic Endocrine Tumor Drug Distributors List Table 153. Pancreatic Endocrine Tumor Drug Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Pancreatic Endocrine Tumor Drug Image Figure 2. Global Pancreatic Endocrine Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pancreatic Endocrine Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pancreatic Endocrine Tumor Drug Sales (2021-2032) & (W Units) Figure 5. Buparlisib Hydrochloride Image Figure 6. Global Buparlisib Hydrochloride Sales YoY Growth (2021-2032) & (W Units) Figure 7. Dovitinib Lactate Image Figure 8. Global Dovitinib Lactate Sales YoY Growth (2021-2032) & (W Units) Figure 9. Fosbretabulin Tromethamine Image Figure 10. Global Fosbretabulin Tromethamine Sales YoY Growth (2021-2032) & (W Units) Figure 11. Lanreotide Acetate Image Figure 12. Global Lanreotide Acetate Sales YoY Growth (2021-2032) & (W Units) Figure 13. MPHE-001B Image Figure 14. Global MPHE-001B Sales YoY Growth (2021-2032) & (W Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 17. Global Pancreatic Endocrine Tumor Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Pancreatic Endocrine Tumor Drug Market Share by Type 2025 VS 2032 Figure 19. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Pancreatic Endocrine Tumor Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 33. Research Center Image Figure 34. Global Research Center Sales YoY Growth (2021-2032) & (W Units) Figure 35. Hospital Image Figure 36. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 37. Global Pancreatic Endocrine Tumor Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Pancreatic Endocrine Tumor Drug Market Share by Application 2025 VS 2032 Figure 39. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Pancreatic Endocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. North America Pancreatic Endocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Pancreatic Endocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Pancreatic Endocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Europe Pancreatic Endocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Pancreatic Endocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Pancreatic Endocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Pancreatic Endocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Latin America Pancreatic Endocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Pancreatic Endocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Pancreatic Endocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Pancreatic Endocrine Tumor Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Pancreatic Endocrine Tumor Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Buparlisib Hydrochloride
  • Dovitinib Lactate
  • Fosbretabulin Tromethamine
  • Lanreotide Acetate
  • MPHE-001B
  • Others
Applications
  • Clinic
  • Research Center
  • Hospital
Companies covered
  • Ipsen S.A.
  • MediaPharma s.r.l.
  • OXiGENE, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pancreatic Endocrine Tumor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pancreatic Endocrine Tumor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pancreatic Endocrine Tumor Drug Market by Type
  6. 1.3.1 Buparlisib Hydrochloride
  7. 1.3.2 Dovitinib Lactate
  8. 1.3.3 Fosbretabulin Tromethamine
  9. 1.3.4 Lanreotide Acetate
  10. 1.3.5 MPHE-001B
  11. 1.3.6 Others
  12. 1.4 Global Pancreatic Endocrine Tumor Drug Market Size by Type
  13. 1.4.1 Global Pancreatic Endocrine Tumor Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Pancreatic Endocrine Tumor Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Pancreatic Endocrine Tumor Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pancreatic Endocrine Tumor Drug Industry Trends
  2. 2.2 Pancreatic Endocrine Tumor Drug Industry Drivers
  3. 2.3 Pancreatic Endocrine Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Pancreatic Endocrine Tumor Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pancreatic Endocrine Tumor Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Pancreatic Endocrine Tumor Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Pancreatic Endocrine Tumor Drug Price (2021-2026)
  4. 3.4 Global Pancreatic Endocrine Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pancreatic Endocrine Tumor Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Pancreatic Endocrine Tumor Drug Company, Product Type & Application
  7. 3.7 Global Pancreatic Endocrine Tumor Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pancreatic Endocrine Tumor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pancreatic Endocrine Tumor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pancreatic Endocrine Tumor Drug Tier 1, Tier 2, and Tier 3
4 Pancreatic Endocrine Tumor Drug Regional Status and Outlook
  1. 4.1 Global Pancreatic Endocrine Tumor Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pancreatic Endocrine Tumor Drug Historic Market Size by Region
  3. 4.2.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pancreatic Endocrine Tumor Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pancreatic Endocrine Tumor Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pancreatic Endocrine Tumor Drug Forecasted Market Size by Region
  7. 4.3.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pancreatic Endocrine Tumor Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pancreatic Endocrine Tumor Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pancreatic Endocrine Tumor Drug by Application
  1. 5.1 Pancreatic Endocrine Tumor Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Research Center
  4. 5.1.3 Hospital
  5. 5.2 Global Pancreatic Endocrine Tumor Drug Market Size by Application
  6. 5.2.1 Global Pancreatic Endocrine Tumor Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Pancreatic Endocrine Tumor Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Pancreatic Endocrine Tumor Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Ipsen S.A.
  2. 6.1.1 Ipsen S.A. Company Information
  3. 6.1.2 Ipsen S.A. Business Overview
  4. 6.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio
  6. 6.1.5 Ipsen S.A. Recent Developments
  7. 6.2 MediaPharma s.r.l.
  8. 6.2.1 MediaPharma s.r.l. Company Information
  9. 6.2.2 MediaPharma s.r.l. Business Overview
  10. 6.2.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio
  12. 6.2.5 MediaPharma s.r.l. Recent Developments
  13. 6.3 OXiGENE, Inc.
  14. 6.3.1 OXiGENE, Inc. Company Information
  15. 6.3.2 OXiGENE, Inc. Business Overview
  16. 6.3.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio
  18. 6.3.5 OXiGENE, Inc. Recent Developments
  19. 6.4 Jiangsu Hengrui Medicine Co., Ltd.
  20. 6.4.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  21. 6.4.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  22. 6.4.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio
  24. 6.4.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  25. 6.5 Novartis AG
  26. 6.5.1 Novartis AG Company Information
  27. 6.5.2 Novartis AG Business Overview
  28. 6.5.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio
  30. 6.5.5 Novartis AG Recent Developments
7 North America by Country
  1. 7.1 North America Pancreatic Endocrine Tumor Drug Sales by Country
  2. 7.1.1 North America Pancreatic Endocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pancreatic Endocrine Tumor Drug Market Size by Country
  6. 7.2.1 North America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pancreatic Endocrine Tumor Drug Sales by Country
  2. 8.1.1 Europe Pancreatic Endocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pancreatic Endocrine Tumor Drug Market Size by Country
  6. 8.2.1 Europe Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Country
  2. 9.1.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pancreatic Endocrine Tumor Drug Sales by Country
  2. 10.1.1 South America Pancreatic Endocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pancreatic Endocrine Tumor Drug Market Size by Country
  6. 10.2.1 South America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country
  2. 11.1.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pancreatic Endocrine Tumor Drug Value Chain Analysis
  2. 12.1.1 Pancreatic Endocrine Tumor Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pancreatic Endocrine Tumor Drug Production Mode & Process
  7. 12.2 Pancreatic Endocrine Tumor Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pancreatic Endocrine Tumor Drug Distributors
  10. 12.2.3 Pancreatic Endocrine Tumor Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst